Is NGEN or RGNX more profitable?

NervGen Pharma has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -3,629.51% -386.54% REGENXBIO -112.58% -220.07% -46.04%

Does the media favor NGEN or RGNX?

In the previous week, REGENXBIO had 14 more articles in the media than NervGen Pharma. MarketBeat recorded 19 mentions for REGENXBIO and 5 mentions for NervGen Pharma. REGENXBIO's average media sentiment score of 0.69 beat NervGen Pharma's score of -0.13 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NGEN or ZURA?

NervGen Pharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A -$31.58M -$0.09 N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is NGEN or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -3,629.51% -386.54% Zura Bio N/A -56.13% -50.15%

Does the media favor NGEN or ZURA?

In the previous week, NervGen Pharma had 1 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for NervGen Pharma and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat NervGen Pharma's score of -0.13 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CCCC or NGEN?

In the previous week, C4 Therapeutics had 9 more articles in the media than NervGen Pharma. MarketBeat recorded 14 mentions for C4 Therapeutics and 5 mentions for NervGen Pharma. C4 Therapeutics' average media sentiment score of 0.59 beat NervGen Pharma's score of -0.13 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EVMN or NGEN more profitable?

Evommune's return on equity of -62.63% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% NervGen Pharma N/A -3,629.51% -386.54%

Does the media refer more to EVMN or NGEN?

In the previous week, Evommune had 10 more articles in the media than NervGen Pharma. MarketBeat recorded 15 mentions for Evommune and 5 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.13 beat Evommune's score of -0.41 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ANL or NGEN?

NervGen Pharma has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 106.00 -$35.53M N/A N/A NervGen Pharma N/A N/A -$31.58M -$0.09 N/A

Is ANL or NGEN more profitable?

Adlai Nortye's return on equity of 0.00% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A NervGen Pharma N/A -3,629.51% -386.54%

Does the media prefer ANL or NGEN?

In the previous week, Adlai Nortye had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for Adlai Nortye and 5 mentions for NervGen Pharma. Adlai Nortye's average media sentiment score of 1.45 beat NervGen Pharma's score of -0.13 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NervGen Pharma (NGEN) Competitors

$1.74 -0.03 (-1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 -0.02 (-0.86%)

As of 07:39 PM Eastern

Compare

NGEN vs. RGNX, ZURA, CCCC, EVMN, and ANL

Should you buy NervGen Pharma stock or one of its competitors? NervGen Pharma's main competitors and comparable companies include REGENXBIO (RGNX), Zura Bio (ZURA), C4 Therapeutics (CCCC), Evommune (EVMN), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NervGen Pharma compare to REGENXBIO?

NervGen Pharma (NASDAQ:NGEN) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

NervGen Pharma presently has a consensus price target of $14.00, suggesting a potential upside of 706.92%. REGENXBIO has a consensus price target of $23.73, suggesting a potential upside of 120.31%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NervGen Pharma is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

NervGen Pharma has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. REGENXBIO's return on equity of -220.07% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-3,629.51%	-386.54%
REGENXBIO	-112.58%	-220.07%	-46.04%

88.1% of REGENXBIO shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NervGen Pharma has higher earnings, but lower revenue than REGENXBIO. NervGen Pharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A
REGENXBIO	$170.44M	4.17	-$193.88M	-$3.79	N/A

In the previous week, REGENXBIO had 14 more articles in the media than NervGen Pharma. MarketBeat recorded 19 mentions for REGENXBIO and 5 mentions for NervGen Pharma. REGENXBIO's average media sentiment score of 0.69 beat NervGen Pharma's score of -0.13 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

REGENXBIO beats NervGen Pharma on 8 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to Zura Bio?

NervGen Pharma (NASDAQ:NGEN) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

61.1% of Zura Bio shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NervGen Pharma had 1 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for NervGen Pharma and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat NervGen Pharma's score of -0.13 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma currently has a consensus target price of $14.00, indicating a potential upside of 706.92%. Zura Bio has a consensus target price of $14.00, indicating a potential upside of 151.35%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NervGen Pharma is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zura Bio's return on equity of -56.13% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-3,629.51%	-386.54%
Zura Bio	N/A	-56.13%	-50.15%

NervGen Pharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Summary

NervGen Pharma and Zura Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

NervGen Pharma has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
NervGen Pharma	N/A	-3,629.51%	-386.54%

NervGen Pharma has lower revenue, but higher earnings than C4 Therapeutics. NervGen Pharma is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, C4 Therapeutics had 9 more articles in the media than NervGen Pharma. MarketBeat recorded 14 mentions for C4 Therapeutics and 5 mentions for NervGen Pharma. C4 Therapeutics' average media sentiment score of 0.59 beat NervGen Pharma's score of -0.13 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics presently has a consensus price target of $7.75, suggesting a potential upside of 82.78%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 706.92%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

C4 Therapeutics and NervGen Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to Evommune?

Evommune (NYSE:EVMN) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Evommune's return on equity of -62.63% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
NervGen Pharma	N/A	-3,629.51%	-386.54%

NervGen Pharma has lower revenue, but higher earnings than Evommune. NervGen Pharma is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	40.75	-$68.87M	-$11.03	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A

Evommune presently has a consensus target price of $43.25, suggesting a potential upside of 196.31%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 706.92%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Evommune had 10 more articles in the media than NervGen Pharma. MarketBeat recorded 15 mentions for Evommune and 5 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.13 beat Evommune's score of -0.41 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evommune and NervGen Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does NervGen Pharma compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 83.02%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 706.92%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Adlai Nortye's return on equity of 0.00% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
NervGen Pharma	N/A	-3,629.51%	-386.54%

NervGen Pharma has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	106.00	-$35.53M	N/A	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A

In the previous week, Adlai Nortye had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for Adlai Nortye and 5 mentions for NervGen Pharma. Adlai Nortye's average media sentiment score of 1.45 beat NervGen Pharma's score of -0.13 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.2% of Adlai Nortye shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adlai Nortye beats NervGen Pharma on 7 of the 12 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$141.91M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	N/A	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	57.83	16.78	12.91	6.24
Net Income	-$31.58M	-$13.32M	$3.45B	$347.60M
7 Day Performance	1.46%	1.74%	1.12%	1.07%
1 Month Performance	-0.29%	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.43%	67.69%	20.77%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	1.8987 of 5 stars	$1.74 -1.4%	$14.00 +706.9%	N/A	$141.91M	N/A	N/A	N/A	News Coverage Earnings Report
RGNX REGENXBIO	3.8717 of 5 stars	$10.59 -0.7%	$23.73 +124.1%	+19.4%	$547.50M	$170.44M	N/A	370	Analyst Upgrade Analyst Revision
ZURA Zura Bio	2.6394 of 5 stars	$5.61 -0.4%	$14.00 +149.6%	+254.1%	$532.28M	N/A	N/A	3	Earnings Report Analyst Forecast
CCCC C4 Therapeutics	1.6036 of 5 stars	$4.26 +4.3%	$7.75 +82.1%	+75.1%	$523.49M	$35.95M	N/A	150	News Coverage Earnings Report Analyst Revision
EVMN Evommune	2.5573 of 5 stars	$14.39 +2.3%	$43.25 +200.6%	N/A	$522.06M	$10M	N/A	45	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. RGNX, ZURA, CCCC, EVMN, and ANL

How does NervGen Pharma compare to REGENXBIO?

Summary

How does NervGen Pharma compare to Zura Bio?

Summary

How does NervGen Pharma compare to C4 Therapeutics?

Summary

How does NervGen Pharma compare to Evommune?

Summary

How does NervGen Pharma compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. RGNX, ZURA, CCCC, EVMN, and ANL

How does NervGen Pharma compare to REGENXBIO?

Do analysts recommend NGEN or RGNX?

Is NGEN or RGNX more profitable?

Do insiders and institutionals hold more shares of NGEN or RGNX?

Which has preferable valuation and earnings, NGEN or RGNX?

Does the media favor NGEN or RGNX?

Summary

How does NervGen Pharma compare to Zura Bio?

Do institutionals & insiders believe in NGEN or ZURA?

Does the media favor NGEN or ZURA?

Do analysts rate NGEN or ZURA?

Is NGEN or ZURA more profitable?

Which has better earnings and valuation, NGEN or ZURA?

Summary

How does NervGen Pharma compare to C4 Therapeutics?

Is CCCC or NGEN more profitable?

Which has preferable earnings & valuation, CCCC or NGEN?

Do institutionals and insiders hold more shares of CCCC or NGEN?

Does the media refer more to CCCC or NGEN?

Do analysts recommend CCCC or NGEN?

Summary

How does NervGen Pharma compare to Evommune?

Is EVMN or NGEN more profitable?

Which has stronger earnings & valuation, EVMN or NGEN?

Do analysts rate EVMN or NGEN?

Does the media refer more to EVMN or NGEN?

Summary

How does NervGen Pharma compare to Adlai Nortye?

Do analysts recommend ANL or NGEN?

Is ANL or NGEN more profitable?

Which has preferable earnings and valuation, ANL or NGEN?

Does the media prefer ANL or NGEN?

Do institutionals & insiders hold more shares of ANL or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools